|
See related Alimta powd for inj information |
|
|
|
Manufacturer |
Eli Lilly |
|
Distributor |
Hong Kong: YC Woo/Macau: Four Star |
|
Contents |
Pemetrexed disodium |
|
Indications |
In combination w/ cisplatin for treatment of chemotherapy-naive patients w/ unresectable malignant pleural mesothelioma. In combination w/ cisplatin as 1st-line treatment or as monotherapy in 2nd-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology. Monotherapy for the maintenance treatment of locally advanced or metastatic NSCLC other than predominantly squamous cell histology in patients whose disease has not progressed following platinum-based chemotherpay. 1st-line should be a platinum doublet w/ gemcitabine, paclitaxel or docetaxel.
Click to view Alimta detailed prescribing infomation |
|
Dosage |
In combination w/ cisplatin 500 mg/m2 of BSA as an IV infusion over 10 min on the 1st day of each 21-day cycle. Cisplatin: 75 mg/m2 BSA infused over 2 hr approx 30 min after completion of the pemetrexed infusion. Monotherapy for NSCLC 500 mg/m2 BSA as an IV infusion over 10 min on the 1st day of each 21-day cycle.
Click to view Alimta detailed prescribing infomation |
|
Overdosage |
View Alimta overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Lactation. Concomitant yellow fever vaccine.
Click to view Alimta detailed prescribing infomation |
|
Special Precautions |
Monitor patients for myelosuppression. Reduce incidence & severity of skin reactions through pretreatment w/ corticosteroid. CrCl <45 mL/min. Avoid NSAIDs w/ long t½ at least 5 days prior to, during or 2 days after therapy. Clinically significant 3rd space fluid. Severe dehydration. Preexisting CV risk factors. Reduce toxicity via vit supplementation. Patients on controlled Na diet (500 mg vial only). Pregnancy.
Click to view Alimta detailed prescribing infomation |
|
Adverse Drug Reactions |
Decreased haemoglobin, neutrophils or granulocytes, leukocytes, platelets & CrCl; diarrhoea, vomiting, stomatitis or pharyngits, nausea, anorexia, constipation, fatigue, sensory neuropathy, elevated creatinine, rash or desquamation, alopecia; conjunctivitis, dyspepsia or heartburn, mucositis, dehydration, taste disturbance, fever, elevation of transaminases, pruritus.
View ADR Monitoring Form |
|
Drug Interactions |
Nephrotoxic drugs eg aminoglycosides, loop diuretics, platinum compd, cyclosporin; probenecid, penicillin; NSAIDs (high dose) eg ibuprofen or aspirin; live vaccines. Diluents containing Ca eg lactated Ringer's inj.
View more drug interactions with Alimta |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Alimta detailed prescribing infomation |
|
Storage |
View Alimta storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Alimta description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Alimta mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Alimta powder for injection |
|
Alimta 100 mg x 1's |
 |
|
Alimta 500 mg x 1's |
 |
|
|
|
Manufacturer: |
Eli Lilly |
|
Distributor: |
Hong Kong: YC Woo
Macau: Four Star |
|
|
|
|
|
